Information processing system and information processing method

Abstract

This information processing system comprises: a first examination unit which examines the quality of a sequence for a first fragmented DNA / RNA datum output from a first sequencer using a quality datum output from the first sequencer and determines at least one first examination datum that shows a result of the examination with respect to a sample extracted from a tissue from a patient; a second examination unit which examines the quality of a sequence for a second fragmented DNA / RNA datum output from a second sequencer using a quality datum output from the second sequencer and determines at least one second examination datum that shows a result of the examination with respect to the sample extracted from the tissue from the patient; and an output unit which outputs the DNA / RNA datum for synthesis use from the first fragmented DNA / RNA datum and the second fragmented DNA / RNA datum on the basis of the first examination datum and the second examination datum.

Description

[Technical field]

[0001] The present invention relates to an information processing system and an information processing method. [Background technology]

[0002] Traditionally, existing pharmaceuticals have been manufactured in advance and stored in pharmacies, and have been prescribed to patients according to a doctor's prescription. In recent years, patients have begun to be given medicines that are suited to their constitution and the characteristics of their illness (hereinafter referred to as personalized medicine).

[0003] In the past, cancer treatments and drugs were selected according to the type of cancer, such as lung cancer, colon cancer, and breast cancer. However, in the 2000s, progress was made in elucidating the molecules (proteins) that cause cancer and the genes that underlie them, and it became possible to use "molecularly targeted drugs" that act on such molecules and genes. Further developments from molecularly targeted drugs have also led to the development of treatments that target the molecules and genes of individual patients. Here, treatments that are appropriate for each individual based not only on the type of cancer but also on the characteristics of the cancer, such as gene mutations, are called "personalized treatments." Traditionally, "personalized treatments" based on cancer genetic information have mainly been carried out based on "cancer gene testing," which examines a small number of genes, and "cancer gene panel testing," which examines a large number of genes simultaneously.

[0004] In recent years, there has been progress in cancer immunotherapy (hereafter referred to as cancer vaccine therapy), which uses the natural immune power of humans to attack and eliminate cancer cells. One type of cancer vaccine therapy is known as a "peptide vaccine." Peptide vaccines contain antigens that serve as markers for cancer. When these antigens are directly injected into the body, the natural immune system of humans detects an abnormality and attacks the antigens that serve as markers for cancer, killing the cancer cells.

[0005] In recent years, we have entered an era where all the genetic mutations of each patient's cancer can be easily identified, and the importance of "peptides" newly generated by these genetic mutations in cancer immunotherapy has been highlighted. These peptides are mutated peptides called "neoantigens." It has become clear that when these peptides are displayed on the surface of cancer cells via human leukocyte antigens (HLA), cytotoxic T lymphocytes (CTL) recognize them as enemies and kill the cancer cells, because they are peptides that are not present on the surface of normal cells. Currently, clinical trials are being conducted in Europe and the United States to verify whether personalized cancer vaccine therapy using "neoantigens" is effective as a cancer treatment or recurrence prevention method. Patent Document 1 also discloses a method for identifying a polypeptide fragment that is immunogenic in a specific human subject and a method for preparing a personalized pharmaceutical composition containing the polypeptide fragment. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 2020-510698 Summary of the Invention [Problem to be solved by the invention]

[0007] Because the types and numbers of mutated peptides called "neoantigens" vary from patient to patient, it is necessary to produce a peptide vaccine from the genetic mutations in the patient's cancer tissue individually for each patient. The peptide vaccine must be delivered to the patient before the patient's disease progresses, but because this production is made to order, if there is an error in one of the multiple steps, that step must be repeated, which creates the problem of delays in providing the vaccine to the patient.

[0008] In the production process of peptide vaccines, fragmented DNA (DeoxyriboNucleic Acid) data is output through a pre-analysis process and an analysis process before the vaccine recipe is created. Here, the pre-analysis process includes, for example, specimen collection, formalin fixation, preparation of a pathological tissue specimen, confirmation of tumor cell ratio, confirmation of a pathological tissue specimen for genetic testing, and nucleic acid extraction from the confirmed specimen. The analysis process includes, for example, library preparation, replication by PCR (Polymerase Chain Reaction), sequencing, and data output. The output data of the sequencer is a collection of data that includes many fragments of DNA / RNA data, affected by the fragmentation performed in the library preparation.

[0009] The output data from the sequencer is not consistent due to the influence of pre-analysis and analytical processes. In particular, it is affected by the quality of the input DNA sample, the variation in the PCR process, and the accuracy of sequencing. Normally, the quality of the output data is guaranteed by implementing validation, internal quality control, and external quality control based on the quality control standards established for each process. However, there are cases where poor quality is discovered at the end of the process, and if redoing is required, there is a problem that vaccine production will be delayed and delivery to patients will be delayed.

[0010] In addition to cancer vaccines, there is also the possibility that similar neoantigens could be used to treat autoimmune diseases, and similar problems exist in personalized medicine for autoimmune diseases.

[0011] The present invention has been made in consideration of the above problems, and aims to provide an information processing system and an information processing method that make it possible to suppress delays in the production of vaccines for personalized medicine. [Means for solving the problem]

[0012] An information processing system according to a first aspect of the present invention is an information processing system that outputs DNA / RNA data for synthesis used to synthesize mutant peptides derived from cancer gene mutations, and includes a first diagnostic unit that diagnoses the quality of the sequence of first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient using the quality data output from the first sequencer and determines at least one first diagnostic data representing a diagnostic result, a second diagnostic unit that diagnoses the quality of the sequence of second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient using the quality data output from the second sequencer and determines at least one second diagnostic data representing a diagnostic result, and an output unit that outputs the DNA / RNA data for synthesis from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data.

[0013] This configuration increases the likelihood that good-quality DNA / RNA data for synthesis will be output to synthesize mutant peptides, and reduces the need for rework due to deterioration in the quality of DNA / RNA data for synthesis, thereby suppressing delays in the production of personalized cancer vaccines.

[0014] An information processing system according to a second aspect of the present invention is an information processing system according to the first aspect, wherein the first diagnostic unit diagnoses the quality of the sequence of the first fragmented DNA / RNA data using quality information of a pre-analytical process performed before the sequencing of the first sequencer in addition to quality data output from the first sequencer to determine the first diagnostic data, and the second diagnostic unit diagnoses the quality of the sequence of the second fragmented DNA / RNA data using quality information of a pre-analytical process performed before the sequencing of the second sequencer in addition to quality data output from the second sequencer to determine the second diagnostic data.

[0015] An information processing system according to a third aspect of the present invention is an information processing system according to the first or second aspect, wherein the output unit may switch between the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and output the switched data as the DNA / RNA data for synthesis.

[0016] An information processing system according to a fourth aspect of the present invention is an information processing system according to the first or second aspect, wherein the output unit may combine a portion of the first fragmented DNA / RNA data and a portion of the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and output the combined data as the DNA / RNA data for synthesis.

[0017] An information processing system according to a fifth aspect of the present invention is an information processing system that outputs DNA / RNA data for synthesis used to synthesize a mutant peptide derived from a gene mutation in a cancer, and is equipped with an output unit that combines first fragmented DNA / RNA data output by a first sequencer for a sample extracted from a tissue of a target patient and second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient, and outputs the combined data as DNA / RNA data for synthesis.

[0018] An information processing system according to a sixth aspect of the present invention is an information processing system according to the fifth aspect, wherein the output section, when outputting the DNA / RNA data for synthesis, may output diagnostic data including a priority order of the mutant peptides together with the DNA / RNA data for synthesis.

[0019] An information processing system according to a seventh aspect of the present invention is an information processing system that outputs DNA / RNA data for synthesis for synthesizing a mutant peptide derived from a gene mutation of a cancer, and is equipped with an output unit that determines the DNA / RNA data for synthesis by taking a majority vote between bases in corresponding orders in first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient, second fragmented DNA / RNA data output by a second sequencer for the sample extracted from the tissue of the target patient, and third fragmented DNA / RNA data output by a third sequencer for the sample extracted from the tissue of the target patient, to determine the order of bases in each of the first fragmented DNA / RNA data.

[0020] An information processing method according to an eighth aspect of the present invention is an information processing method for outputting DNA / RNA data for synthesis for synthesizing a mutant peptide derived from a gene mutation of a cancer, and includes the steps of: diagnosing the quality of the sequence of first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient using the quality data output from the first sequencer, and determining at least one first diagnostic data representing a diagnostic result; diagnosing the quality of the sequence of second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of a target patient using the quality data output from the second sequencer, and determining at least one second diagnostic data representing a diagnostic result; and outputting the DNA / RNA data for synthesis from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data.

[0021] An information processing method according to a ninth aspect of the present invention is an information processing method that outputs DNA / RNA data for synthesis for synthesizing a mutant peptide derived from a gene mutation of a cancer, and includes a step of combining first fragmented DNA / RNA data output by a first sequencer for a sample extracted from a tissue of a target patient and second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient, and outputting the combined data as DNA / RNA data for synthesis.

[0022] An information processing method according to a tenth aspect of the present invention is an information processing method for outputting DNA / RNA data for synthesis used to synthesize a mutant peptide derived from a gene mutation of a cancer, and includes a step of determining the DNA / RNA data for synthesis by taking a majority vote between bases in corresponding orders in first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient, second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient, and third fragmented DNA / RNA data output by a third sequencer for the sample extracted from the tissue of the target patient, to determine the order of bases in each of the first fragmented DNA / RNA data. Effect of the Invention

[0023] According to one embodiment of the present invention, the likelihood of outputting high-quality DNA / RNA data for synthesis in order to synthesize mutant peptides is improved, and the need for rework due to deterioration in the quality of DNA / RNA data for synthesis is reduced, thereby suppressing delays in the production of personalized cancer vaccines. [Brief description of the drawings]

[0024] [Figure 1] FIG. 1 is a schematic diagram showing an example of a manufacturing process for a personalized cancer vaccine. [Diagram 2] 1 is a schematic block diagram of an information processing system according to a first embodiment. [Figure 3A] FIG. 4 is a schematic diagram showing a process of an output unit according to the first embodiment. [Figure 3B] FIG. 11 is a schematic diagram showing a process of an output unit according to Modification 1 of the first embodiment. [Figure 4] FIG. 11 is a schematic block diagram of an information processing system according to a second modified example of the first embodiment. [Diagram 5] FIG. 11 is a schematic block diagram of an information processing system according to a second embodiment. [Figure 6] FIG. 11 is a schematic block diagram of an information processing system according to a third embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] Hereinafter, each embodiment will be described with reference to the drawings. However, more detailed description than necessary may be omitted. For example, detailed description of already well-known matters or duplicate description of substantially the same configuration may be omitted. This is to avoid the following description becoming unnecessarily redundant and to facilitate understanding by those skilled in the art.

[0026] FIG. 1 is a schematic diagram showing an example of a manufacturing process for a personalized cancer vaccine.

[0027] (Step S10) First, a doctor performs surgery to remove cancer tissue from a patient, and extracts a DNA / RNA sample from the cancer tissue or tissue specimen.

[0028] (Step S20) Next, the DNA / RNA sample is transported and stored, for example, at a vendor, where the vendor owns a next-generation sequencer.

[0029] (Step S30) Next, the genome of the DNA / RNA sample is read by a next-generation sequencer, and DNA / RNA data for synthesis is output, which is used to synthesize mutant peptides (i.e., neoantigens) derived from cancer gene mutations.

[0030] (Step S40) Next, a recipe for a personalized cancer vaccine is created from the DNA / RNA data for synthesis.

[0031] (Step S50) Next, a personalized cancer vaccine is manufactured based on the created recipe.

[0032] (Step S60) Next, the manufactured personalized cancer vaccine is transported and stored at the hospital.

[0033] (Step S70) The personalized cancer vaccine is injected into the target patient.

[0034] If the quality of the DNA / RNA data for synthesis deteriorates, it is necessary to start over from the transportation of the sample in step S20, which causes a problem of delaying the production of the personalized cancer vaccine. In response to this problem, the present embodiment provides an information processing system and an information processing method for suppressing deterioration in the quality of the DNA / RNA data for synthesis.

[0035] <First embodiment: Output switching> In this embodiment, the sequencers are parallelized, and output data is integrated based on a diagnostic function for diagnosing the operation process including quality information for each process before analysis and / or the output quality data. Here, the quality data includes at least one of the following, for example: depth of coverage (target region), uniformity of coverage (target region), GC bias, Ti / Tv ratio, base call quality scores, mapping quality, duplicate read success rate and removal of duplicate reads, first base read success, decline in signal intensity, and DNA strand bias.

[0036] When collecting samples, it is preferable to use FFPE samples, and the warm ischemia time (from cessation of blood flow to extraction) and cold ischemia time (from extraction to fixation) are important.

[0037] Regarding the quality standard of the extracted nucleic acid, the ΔCt value (ΔΔCq), DIN value, Q-value, DV200, etc. may be used as the quality of the nucleic acid (mainly evaluating the degree of fragmentation).

[0038] Regarding the quality standard of the library, an appropriate quality check may be performed after the library preparation, and an index may be set in advance to determine whether or not it is appropriate to proceed to sequence analysis. The index may be the amount of DNA or the fragment size.

[0039] Fig. 2 is a schematic block diagram of an information processing system according to the first embodiment. As shown in Fig. 2, the information processing system 1 outputs DNA / RNA data for synthesis used to synthesize a mutant peptide derived from a gene mutation of a cancer, and includes a processor 10. The processor 10 functions as a first diagnostic unit 11, a second diagnostic unit 12, and an output unit 13 by loading a program into a memory (not shown) and executing a series of instructions included in the program.

[0040] The first sequencer 21 is, for example, a next-generation sequencer, which performs genome sequencing on a sample extracted from a cancer tissue of a subject patient to generate first fragmented DNA / RNA data and quality data indicating the quality of the genome sequence. The first sequencer 21 may have an HLA typing function.

[0041] Similarly, the second sequencer 22 is, for example, a next-generation sequencer, which performs genome sequencing on a sample extracted from the cancer tissue of the target patient and generates second fragmented DNA / RNA data and quality data indicating the quality of the genome sequence.

[0042] The first diagnostic unit 11 acquires the first fragmented DNA / RNA data and quality data from the first sequencer 21. The first diagnostic unit 11 diagnoses the quality of the sequence of the first fragmented DNA / RNA data output by the first sequencer for a sample extracted from the tissue of a subject patient, using the quality data output from the first sequencer, and determines at least one piece of first diagnostic data representing a diagnosis result.

[0043] The second diagnostic unit 12 acquires the second fragmented DNA / RNA data and quality data from the second sequencer 22. The second diagnostic unit 12 diagnoses the quality of the sequence of the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the subject patient using the quality data output from the second sequencer, and determines at least one piece of second diagnostic data representing the diagnosis result.

[0044] The output unit 13 acquires the first fragmented DNA / RNA data from the first sequencer 21, acquires the second fragmented DNA / RNA data from the second sequencer 22, acquires the first diagnostic data from the first diagnostic unit 11, and acquires the second diagnostic data from the second diagnostic unit 12. The output unit 13 outputs the DNA / RNA data to be synthesized from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data.

[0045] This configuration increases the likelihood that good-quality DNA / RNA data for synthesis will be output to synthesize mutant peptides, and reduces the need for rework due to deterioration in the quality of DNA / RNA data for synthesis, thereby suppressing delays in the production of personalized cancer vaccines.

[0046] Fig. 3A is a schematic diagram showing the processing of the output unit according to the first embodiment. In the first embodiment, as shown in Fig. 3A, the output unit 13 switches between the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and outputs the switched data as the DNA / RNA data to be synthesized. More specifically, the output unit 13 determines whether the first fragmented DNA / RNA data or the second fragmented DNA / RNA data is more appropriate based on the first diagnostic data and the second diagnostic data, and switches the output.

[0047] Specifically, for example, the output unit 13 may output only fragmented DNA / RNA data having more excellent indices than a set threshold among the multiple indices set for the diagnostic data. According to this configuration, fragmented DNA / RNA data having many excellent indices is output for synthesizing mutant peptides, so that redoing due to deterioration in the quality of DNA / RNA data for synthesis is suppressed, thereby suppressing delays in the production of personalized cancer vaccines.

[0048] <Modification 1 of the First Embodiment: Output Mixing> Fig. 3B is a schematic diagram showing the processing of the output unit according to the first modified example of the first embodiment. As shown in Fig. 3B, the output unit 13 may combine a part of the first fragmented DNA / RNA data and a part of the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and output the combined data as the DNA / RNA data to be synthesized.

[0049] Specifically, for example, when there is an index for each piece of fragmented DNA / RNA data, the output unit 13c may output a predetermined number of pieces of fragmented DNA / RNA data in order of superiority of the index.

[0050] Alternatively, the output unit 13c may, for example, analyze the frequency of fragmentation data contained in the output data of both the first sequencer 21 and the second sequencer 22 (i.e., the first fragmented DNA / RNA data, the second fragmented DNA / RNA data), and output the cross-sectioned data in order of frequency.

[0051] <Modification 2 of the First Embodiment> Fig. 4 is a schematic block diagram of an information processing system according to Modification 2 of the first embodiment. The information processing system 1b in Fig. 4 is different from the information processing system 1 in Fig. 2 in that the processing of the processor 10b is different, the first diagnostic unit 11 is changed to a first diagnostic unit 11b, and the second diagnostic unit 12 is changed to a second diagnostic unit 12b.

[0052] The first diagnostic unit 11b acquires an operation log including quality information of a pre-analysis process. The first diagnostic unit diagnoses the quality of the sequence of the first fragmented DNA / RNA data using the quality information of a pre-analysis process performed before the sequence of the first sequencer 21 in addition to the quality data output from the first sequencer 21, and determines the first diagnostic data. Specifically, for example, the first diagnostic unit 11b may diagnose the quality as good if the quality data meets a first criterion and the quality information meets a second criterion, and may determine the quality as poor otherwise, and determine the first diagnostic data representing the diagnosis result.

[0053] Similarly, the second diagnostic unit 12b acquires an operation log including quality information of the pre-analysis process. The second diagnostic unit 12b uses the quality information of the pre-analysis process performed before the sequence of the second sequencer 22 in addition to the quality data output from the second sequencer 22 to diagnose the quality of the sequence of the second fragmented DNA / RNA data and determine the second diagnostic data. Specifically, for example, if this quality data meets a first criterion and this quality information meets a second criterion, the second diagnostic unit 12b may diagnose the quality as good, and otherwise determine the quality as poor, and determine the first diagnostic data representing the diagnosis result.

[0054] <Modification 3 of the First Embodiment> The output unit 13 may filter and limit the amount of DNA / RNA data to be synthesized based on the first and second diagnostic data, for the double output data consisting of the first and second fragmented DNA / RNA data. This filter may use at least one or more statistical values ​​such as number limit, magnitude of diagnostic data value for each read, and overlapping reads.

[0055] This configuration increases the likelihood that good-quality DNA / RNA data for synthesis will be output to synthesize mutant peptides, and reduces the need for rework due to deterioration in the quality of DNA / RNA data for synthesis, thereby suppressing delays in the production of personalized cancer vaccines.

[0056] <Second embodiment: Output coupling> Fig. 5 is a schematic block diagram of an information processing system according to a second embodiment. As shown in Fig. 5, the information processing system 1c includes a processor 10c. The processor 10c functions as an output unit 13c by loading a program into a memory (not shown) and executing a series of instructions included in the program. The output unit 13c combines the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the target patient and the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the target patient, and outputs the combined data as DNA / RNA data for synthesis.

[0057] Specifically, for example, when multiple indicators of diagnostic data exceed a threshold, the output unit 13c may combine both sets of data and output them as doubled data.

[0058] Alternatively, the output unit 13c may, for example, compare both pieces of output data, and if the difference between them is small, combine both pieces of data and output it as double data.

[0059] Furthermore, when outputting the DNA / RNA data for synthesis, the output unit 13c may output diagnostic data including the priority order of the mutant peptides (neoantigens) together with the DNA / RNA data for synthesis. The priority order may be determined based on the quality information and / or the quality data, and the higher the quality, the higher the priority order may be set. According to this configuration, DNA / RNA data for synthesis with high quality is preferentially used to synthesize mutant peptides, and redoing due to deterioration in the quality of DNA / RNA data for synthesis is suppressed, thereby suppressing delays in the production of personalized cancer vaccines.

[0060] In the first and second embodiments, the number of parallel connections is described as two, but the number of parallel connections may be three or more, and may be determined by the amount of sample collected during surgery.

[0061] <Third embodiment: majority vote> Fig. 6 is a schematic block diagram of an information processing system according to a third embodiment. As shown in Fig. 6, the information processing system 1d includes a processor 10d. The processor 10d loads a program into a memory (not shown) and executes a series of instructions included in the program to function as an output unit 13d.

[0062] The output unit 13d acquires the first fragmented DNA / RNA data from the first sequencer 21. The output unit 13d also acquires the second fragmented DNA / RNA data from the second sequencer 22. The output unit 13d also acquires the third fragmented DNA / RNA data from the third sequencer 23.

[0063] The output unit 13d determines the DNA / RNA data to be synthesized by determining the order of bases in each of the corresponding orders of the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the target patient, the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the target patient, and the third fragmented DNA / RNA data output by the third sequencer for the sample extracted from the tissue of the target patient, by a majority vote.

[0064] This configuration improves the accuracy of the synthetic DNA / RNA data used to synthesize mutant peptides, thereby reducing delays in the production of personalized cancer vaccines.

[0065] In addition to cancer vaccines, similar neoantigens may be used to treat autoimmune diseases, and similar embodiments can be used in personalized medicine for autoimmune diseases.

[0066] At least a part of the information processing system 1 described in the above embodiment may be configured with hardware or software. When configured with software, a program that realizes at least a part of the functions of the information processing system 1 may be stored in a computer-readable recording medium and read and executed by a computer. The recording medium is not limited to a removable one such as a magnetic disk or an optical disk, but may be a fixed recording medium such as a hard disk device or a memory.

[0067] Also, a program that realizes at least a part of the functions of the information processing system 1 may be distributed via a communication line (including wireless communication) such as the Internet. Furthermore, the program may be encrypted, modulated, or compressed and distributed via a wired line or wireless line such as the Internet, or stored in a recording medium.

[0068] Furthermore, the information processing system 1 may be operated by one or more information devices. When multiple information devices are used, one of the devices may be a computer, and the computer may execute a predetermined program to realize the function as at least one of the means of the information processing system 1.

[0069] In the method invention, all the steps may be realized by automatic control using a computer. Alternatively, each step may be performed by a computer while the progress between steps is controlled manually. Furthermore, at least some of the steps may be performed manually.

[0070] As described above, the present invention is not limited to the above-described embodiment as it is, and in the implementation stage, the components can be modified and embodied without departing from the gist of the invention. In addition, various inventions can be formed by appropriately combining the multiple components disclosed in the above-described embodiment. For example, some components may be deleted from all the components shown in the embodiment. Furthermore, components from different embodiments may be appropriately combined. [Explanation of symbols]

[0071] 1, 1b, 1c, 1d Information Processing Systems 10, 10b, 10c, 10d processors 11, 11b First diagnostic section 12, 12b Second diagnostic section 13, 13c, 13d Output section 21 First sequencer 22 Second sequencer 23 3rd sequencer

Claims

1. An information processing system that outputs DNA / RNA synthesis data used to synthesize mutant peptides derived from cancer gene mutations using multiple parallel sequencers, comprising: A first diagnostic unit that uses quality data output from the first sequencer to diagnose the quality of the sequence of the first fragmented DNA / RNA data output from the first sequencer for a sample extracted from the tissue of a target patient, and determines at least one first diagnostic data representing a diagnostic result; A second diagnostic unit that uses the quality data output from the second sequencer to diagnose the quality of the sequence of the second fragmented DNA / RNA data output from the second sequencer for the sample extracted from the tissue of the subject patient, and determines at least one second diagnostic data representing the diagnosis result; an output unit that outputs the DNA / RNA data to be synthesized from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the index of the first diagnostic data, the index of the second diagnostic data, and a set threshold value for each index; An information processing system comprising:

2. The first diagnostic unit diagnoses the quality of the sequence of the first fragmented DNA / RNA data using quality information of a pre-analysis process performed before the sequence of the first sequencer in addition to the quality data output from the first sequencer, and determines the first diagnostic data; The second diagnostic unit determines the second diagnostic data by diagnosing the quality of the sequence of the second fragmented DNA / RNA data using quality information of a pre-analysis process performed before the sequence of the second sequencer in addition to the quality data output from the second sequencer. The information processing system according to claim 1 .

3. The output unit switches between the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and outputs the switched data as the DNA / RNA data to be synthesized.

3. The information processing system according to claim 1 or 2.

4. The output unit combines a part of the first fragmented DNA / RNA data and a part of the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and outputs the combined DNA / RNA data.

3. The information processing system according to claim 1 or 2.

5. An information processing method implemented by a computer that outputs DNA / RNA data for synthesis to synthesize mutant peptides derived from gene mutations in cancer using multiple parallel sequencers, comprising: A step of diagnosing the quality of the sequence of the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the subject patient using the quality data output from the first sequencer, and determining at least one first diagnostic data representing the diagnostic result; A step of diagnosing the quality of the sequence of the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the subject patient using the quality data output from the second sequencer, and determining at least one second diagnostic data representing the diagnosis result; a step of outputting the DNA / RNA data to be synthesized from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data, based on an index of the first diagnostic data, an index of the second diagnostic data, and a set threshold value of each index; An information processing method comprising the steps of:

Images